Re: Boys washing out of eteplirsen to participate in suvodirsen trial.
Schmiggins - the company's targets have slipped, priorities changed without a word. One of the tweeters posted something about a business decision surrounding the abandonment of antibiotics and seems out of touch with how many employees the Company publishes hiring. But heck what's the difference between 100 versus over 150. At the rate new employees have streamed through the doors in the past two years it is a wonder any programs have made progress let alone gain focus.
The exon skipping programs are languishing. The company's first phase 3 program had an ignored completion date come and go [no surprise]. The ongoing "extension" study of the phase 2 on the original 12 boys is still listed both on the clinical trial site and Sarepta's website. Only on the clinical trial site it is listed as unknown status with the last company update in 2016. Is that because some of the original boys in the trial are only assessing exondys 51 through this trial?
The once promising science of morpholinos seems to have been shoved to the side.
A recent glassdoor review of working at Sarepta. "Pros - Decent Salary. Catered Lunch on Weds/Fri. Free Snacks. Ok Benefits (Stock Options and RSUs)" "Cons - "Departments do not work together as a team. -No one want to take responsibilities."